Cargando…
Development and validation of cuproptosis-related gene signature in the prognostic prediction of liver cancer
Liver cancer is a generic term referring to several cancer types arising from the liver. Every year, liver cancer causes lots of deaths and other burdens to the people all over the world. Though the techniques in the diagnosis and therapy of liver cancer have undergone significant advances, the curr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413147/ https://www.ncbi.nlm.nih.gov/pubmed/36033443 http://dx.doi.org/10.3389/fonc.2022.985484 |
_version_ | 1784775668597260288 |
---|---|
author | Liu, Yanqing Liu, Yang Ye, Shujun Feng, Huijin Ma, Lianjun |
author_facet | Liu, Yanqing Liu, Yang Ye, Shujun Feng, Huijin Ma, Lianjun |
author_sort | Liu, Yanqing |
collection | PubMed |
description | Liver cancer is a generic term referring to several cancer types arising from the liver. Every year, liver cancer causes lots of deaths and other burdens to the people all over the world. Though the techniques in the diagnosis and therapy of liver cancer have undergone significant advances, the current status of treating liver cancer is not satisfactory enough. The improvement of techniques for the prognosis of liver cancer patients will be a great supplement for the treatment of liver cancer. Cuproptosis is a newly identified regulatory cell death type, which may have a close connection to liver cancer pathology. Here, we developed a prognostic model for liver cancer based on the cuproptosis-related mRNAs and lncRNAs. This model can not only effectively predict the potential survival of liver cancer patients, but also be applied to evaluate the infiltration of immune cell, tumor mutation burden, and sensitivity to anti-tumor drugs in liver cancer. In addition, this model has been successfully validated in lots of liver cancer patients’ data. In summary, we wish this model can become a helpful tool for clinical use in the therapy of liver cancer. |
format | Online Article Text |
id | pubmed-9413147 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94131472022-08-27 Development and validation of cuproptosis-related gene signature in the prognostic prediction of liver cancer Liu, Yanqing Liu, Yang Ye, Shujun Feng, Huijin Ma, Lianjun Front Oncol Oncology Liver cancer is a generic term referring to several cancer types arising from the liver. Every year, liver cancer causes lots of deaths and other burdens to the people all over the world. Though the techniques in the diagnosis and therapy of liver cancer have undergone significant advances, the current status of treating liver cancer is not satisfactory enough. The improvement of techniques for the prognosis of liver cancer patients will be a great supplement for the treatment of liver cancer. Cuproptosis is a newly identified regulatory cell death type, which may have a close connection to liver cancer pathology. Here, we developed a prognostic model for liver cancer based on the cuproptosis-related mRNAs and lncRNAs. This model can not only effectively predict the potential survival of liver cancer patients, but also be applied to evaluate the infiltration of immune cell, tumor mutation burden, and sensitivity to anti-tumor drugs in liver cancer. In addition, this model has been successfully validated in lots of liver cancer patients’ data. In summary, we wish this model can become a helpful tool for clinical use in the therapy of liver cancer. Frontiers Media S.A. 2022-08-12 /pmc/articles/PMC9413147/ /pubmed/36033443 http://dx.doi.org/10.3389/fonc.2022.985484 Text en Copyright © 2022 Liu, Liu, Ye, Feng and Ma https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Liu, Yanqing Liu, Yang Ye, Shujun Feng, Huijin Ma, Lianjun Development and validation of cuproptosis-related gene signature in the prognostic prediction of liver cancer |
title | Development and validation of cuproptosis-related gene signature in the prognostic prediction of liver cancer |
title_full | Development and validation of cuproptosis-related gene signature in the prognostic prediction of liver cancer |
title_fullStr | Development and validation of cuproptosis-related gene signature in the prognostic prediction of liver cancer |
title_full_unstemmed | Development and validation of cuproptosis-related gene signature in the prognostic prediction of liver cancer |
title_short | Development and validation of cuproptosis-related gene signature in the prognostic prediction of liver cancer |
title_sort | development and validation of cuproptosis-related gene signature in the prognostic prediction of liver cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413147/ https://www.ncbi.nlm.nih.gov/pubmed/36033443 http://dx.doi.org/10.3389/fonc.2022.985484 |
work_keys_str_mv | AT liuyanqing developmentandvalidationofcuproptosisrelatedgenesignatureintheprognosticpredictionoflivercancer AT liuyang developmentandvalidationofcuproptosisrelatedgenesignatureintheprognosticpredictionoflivercancer AT yeshujun developmentandvalidationofcuproptosisrelatedgenesignatureintheprognosticpredictionoflivercancer AT fenghuijin developmentandvalidationofcuproptosisrelatedgenesignatureintheprognosticpredictionoflivercancer AT malianjun developmentandvalidationofcuproptosisrelatedgenesignatureintheprognosticpredictionoflivercancer |